In April, the FDA rejected GlaxoSmithKline's request for a pediatric indication for rosiglitazone, citing concern about statistical limitations with regard to efficacy and certain adverse effects of rosiglitazone therapy. However, GlaxoSmithKline continues to work with the FDA in pursuit of the pediatric indication, according to the company.